| Literature DB >> 11213099 |
S Nishiguchi, S Shiomi, S Nakatani, T Takeda, K Fukuda, A Tamori, D Habu, T Tanaka.
Abstract
In a prospective randomised controlled study, 90 patients with chronic active hepatitis C and compensated cirrhosis were assigned symptomatic treatment or interferon alfa (IFN-alpha). We report data on decompensation, detection of hepatocellular carcinoma, and mortality rates. IFN-alpha gave a sustained response in only a small proportion of patients, but worsening of compensated cirrhosis was prevented and development of hepatocellular carcinoma was inhibited, increasing the survival rate. The risk ratio of IFN-alpha versus symptomatic treatment decreased by 0.250 for progression to Child-Pugh grade B, 0.256 for detection of hepatocellular carcinoma, and 0.135 for a fatal outcome.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11213099 DOI： 10.1016/S0140-6736(00)03595-9
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321